RTP Mobile Logo
Select Publications

Abarca T et al. Improved survival for extremity soft tissue sarcoma treated in high-volume facilities. J Surg Oncol 2018;117(7):1479-86. Abstract

American Cancer Society. Cancer Facts & Figures 2019. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2019.html

Bagaria SP et al. Improving long-term outcomes for patients with extra-abdominal soft tissue sarcoma regionalization to high-volume centers, improved compliance with guidelines or both? Sarcoma 2018;2018:8141056. Abstract

Bagaria SP et al. The volume-outcome relationship in retroperitoneal soft tissue sarcoma: Evidence of improved short- and long-term outcomes at high-volume institutions. Sarcoma 2018;2018:3056562. Abstract

Baldini EH et al. Neoadjuvant chemotherapy, concurrent chemoradiation, and adjuvant chemotherapy for high-risk extremity soft tissue sarcoma. Am Soc Clin Oncol Educ Book 2018;38:910-5. Abstract

Casali PG et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29(Suppl 4):51-67. Abstract

Clasby R et al. Variable management of soft tissue sarcoma: Regional audit with implications for specialist care. Br J Surg 1997;84(12):1692-6. Abstract

Coindre JM. Grading of soft tissue sarcomas: Review and update. Arch Pathol Lab Med 2006;130(10):1448-53. Abstract

Cote GM et al. Next-generation sequencing for patients with sarcoma: A single center experience. Oncologist 2018;23(2):234-42. Abstract

D’Adamo DR. Appraising the current role of chemotherapy for the treatment of sarcoma. Semin Oncol 2011;38(Suppl 3):19-29. Abstract

D’Angelo SP et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): Two open-label, non-comparative, randomized, phase 2 trials. Lancet Oncol 2018;19(3):416-26. Abstract

Demetri GD et al. Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine. J Clin Oncol 2017;35(30):3433-9. Abstract

Demetri GD et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: Results of a phase III randomized multicenter clinical trial. J Clin Oncol 2016;34(8):786-93. Abstract

Gronchi A et al. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Final results of a randomized clinical trial from the Italian Sarcoma Group, the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG), and the Polish Sarcoma Group (PSG). ASCO 2019;Abstract 11000.

Grünwald V et al. Randomized comparison of pazopanib (PAZ) and doxorubicin (DOX) in the first line treatment of metastatic soft tissue sarcoma (STS) in elderly patients (pts): Results of a phase II study (EPAZ). ASCO 2018;Abstract 11506.

Guillon MA et al. Clinical characteristics and prognosis of osteosarcoma in young children: A retrospective series of 15 cases. BMC Cancer 2011;11:407. Abstract

Gustafson P et al. Soft tissue sarcoma should be treated at a tumor center. A comparison of quality of surgery in 375 patients. Acta Orthop Scand 1994;65(1):47-50. Abstract

Gutierrez JC et al. Should soft tissue sarcomas be treated at high-volume centers? An analysis of 4205 patients. Ann Surg 2007;245:952-8. Abstract

Judson I et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: A randomized controlled phase 3 trial. Lancet Oncol 2014;15(4):415-23. Abstract

Le Cesne A et al. Results of a prospective randomized phase III T-SAR trial comparing trabectedin (T) vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS): A French Sarcoma Group (FSG) trial. ASCO 2018;Abstract 11508.

Le Cesne A et al. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: Pooled analysis of two STBSG-EORTC phase III clinical trials. Ann Oncol 2014;25(12):2425-32. Abstract

Lewis JJ, Brennan MF. Soft tissue sarcomas. Curr Probl Surg 1996;33(10):817-72. Abstract

Maki RG et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: Results of Sarcoma Alliance for Research Through Collaboration study 002 [corrected]. J Clin Oncol 2007;25(19):2755-63. Abstract

Mankin HJ et al. The hazards of the biopsy, revisited. Members of the Musculoskeletal Tumor Society. J Bone Joint Surg Am 1996;78(5):656-63. Abstract

Noujaim J et al. Histology-driven therapy: The importance of diagnostic accuracy in guiding systemic therapy of soft tissue tumors. Int J Surg Pathol 2016;24(1):5-15. Abstract

O’Sullivan B et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: A randomized trial. Lancet 2002;359(9325):2235-41. Abstract

Pervaiz N et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008;113(3):573-81. Abstract

Presant CA et al. Soft-tissue and bone sarcoma histopathology peer review: The frequency of disagreement in diagnosis and the need for second pathology opinions. The Southeastern Cancer Study Group experience. J Clin Oncol 1986;4(11):1658-61. Abstract

Rosenberg SA et al. The treatment of soft-tissue sarcomas of the extremities: Prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982;196(3):305-15. Abstract

Schöffski P et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A randomized, open-label, multicenter, phase 3 trial. Lancet 2016;387(10028):1629-37. Abstract

Seddon B et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): A randomized controlled phase 3 trial. Lancet Oncol 2017;18(10):1397-410. Abstract

Siegel RL et al. Cancer statistics, 2018. CA Cancer J Clin 2018;68(1):7-30. Abstract

Tap WD et al. ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS). ASCO 2019;Abstract LBA3.

Tawbi HA et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): A multicenter, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 2017;18(11):1493-501. Abstract

van der Graaf WT et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomized, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379(9829):1879-86. Abstract

von Mehren M et al. Soft tissue sarcoma, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2018;16(5):536-63. Abstract

Voss RK et al. Adherence to National Comprehensive Cancer Network guidelines is associated with improved survival for patients with stage 2A and stages 2B and 3 extremity and superficial trunk soft tissue sarcoma. Ann Surg Oncol 2017;24(11):3271-8. Abstract

Woll PJ et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): A multicenter randomized controlled trial. Lancet Oncol 2012;13(10):1045-54. Abstract